HIV treatment study with Bictegravir medication monitoring
Part of Infections clinical trials.
This study looks at how well HIV-1 patients take their medication (bictegravir/emtricitabine/tenofovir) and how that relates to how well the virus is controlled. It uses a special pill bottle cap that records when the bottle is opened, so the research team can see if the medicine is being taken as prescribed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and living with HIV-1.
- You are either about to start or currently taking a medication that includes bictegravir, emtricitabine, and tenofovir (often called B/F/TAF).
- This could be your first HIV treatment, or you are switching from another medication, or you have had treatment failure before.
- You agree to use an electronic cap on your pill bottle that tracks when it is opened.
- You are not pregnant.
- You are not living in a facility where someone else manages your medications, and you do not have a legal guardian making decisions for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at where HIV hides in the body (called the viral reservoir) in men whose HIV is well controlled with Biktarvy. Researchers want to see how the levels of HIV medicines in the body relate to these hidden virus cells, which may help improve future treatments.
This study tests a special pill that has a sensor inside, which sends information to your doctor or care team to help you remember to take your HIV medication. It is for people who sometimes miss doses and want extra support.
This study looks at a way to help people take their HIV medicines as prescribed. It focuses on people who are HIV-positive and not currently taking their treatment consistently.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This study tests a program to help people living with HIV who have difficulty taking their medications consistently. The goal is to see if extra support can improve health outcomes.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
Hear when a new HIV Antiretroviral Therapy (ART) Adherence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.